Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression-Reference-Cited by-同舟云学术

Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression

Published:2007-11 Issue:5 Volume:52 Page:1381-1387
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Lein Michael,Wirth Manfred,Miller Kurt,Eickenberg Hans-Udo,Weißbach Lothar,Schmidt Katja,Haus Ulrike,Stephan Carsten,Meissner Sven,Loening Stefan A.,Jung Klaus

Publisher

Elsevier BV

Subject

Urology

Reference27 articles.

1. Cancer statistics, 2006;Jemal;CA Cancer J Clin,2006

2. Skeletal complications of malignancy;Coleman;Cancer,1997

3. Management of the spectrum of hormone refractory prostate cancer;Clarke;Eur Urol,2006

4. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer;Saad;J Natl Cancer Inst,2004

5. Natural history and treatment of bone complications in prostate cancer;Saad;Eur Urol,2006

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic and prognostic significance of tartrate‐resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real‐world multi‐institutional study;International Journal of Urology;2022-10-28

2. Bone remodeling markers and bone cancer;Bone Cancer;2022

3. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS);BMC Cancer;2021-02-04

4. Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: A case control study;Nigerian Journal of Clinical Practice;2020

5. Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor‑treated patients with non‑small cell lung cancer exhibiting bone metastasis;Oncology Letters;2019-09-16